ABLIVA Trademark

Trademark Overview

On Wednesday, July 15, 2020, a trademark application was filed for ABLIVA with the United States Patent and Trademark Office. The USPTO has given the ABLIVA trademark a serial number of 79293512. The federal status of this trademark filing is REGISTERED as of Tuesday, September 7, 2021. This trademark is owned by Abliva AB. The ABLIVA trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Medical research; research relating to biotechnology; clinical research in the field of mitochondrial diseases; conducting clinical trials for pharmaceutical products for others
abliva

General Information

Serial Number79293512
Word MarkABLIVA
Filing DateWednesday, July 15, 2020
Status700 - REGISTERED
Status DateTuesday, September 7, 2021
Registration Number6473368
Registration DateTuesday, September 7, 2021
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 22, 2021

Trademark Statements

Goods and ServicesMedical research; research relating to biotechnology; clinical research in the field of mitochondrial diseases; conducting clinical trials for pharmaceutical products for others

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, September 18, 2020
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAbliva AB
Party Type30 - Original Registrant
Legal Entity Type64 - NOT AVAILABLE
AddressSE
Party NameAbliva AB
Party Type20 - Owner at Publication
Legal Entity Type64 - NOT AVAILABLE
AddressSE
Party NameAbliva AB
Party Type10 - Original Applicant
Legal Entity Type64 - NOT AVAILABLE
AddressSE

Trademark Events

Event DateEvent Description
Sunday, January 1, 2023NEW REPRESENTATIVE AT IB RECEIVED
Sunday, March 13, 2022FINAL DECISION TRANSACTION PROCESSED BY IB
Tuesday, February 22, 2022FINAL DISPOSITION NOTICE SENT TO IB
Tuesday, February 22, 2022FINAL DISPOSITION PROCESSED
Tuesday, December 7, 2021FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Thursday, October 28, 2021NEW REPRESENTATIVE AT IB RECEIVED
Tuesday, September 7, 2021REGISTERED-PRINCIPAL REGISTER
Tuesday, June 22, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 22, 2021PUBLISHED FOR OPPOSITION
Wednesday, June 2, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, May 17, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, May 15, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, May 14, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, May 14, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, December 6, 2020REFUSAL PROCESSED BY IB
Wednesday, November 18, 2020NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Wednesday, November 18, 2020REFUSAL PROCESSED BY MPU
Thursday, October 29, 2020NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, October 28, 2020NON-FINAL ACTION WRITTEN
Wednesday, October 28, 2020ASSIGNED TO EXAMINER
Tuesday, September 22, 2020APPLICATION FILING RECEIPT MAILED
Friday, September 18, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, September 17, 2020SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

abliva research clinical pharmaceutical trials products others conducting mitochondrial relating biotechnology